Ctcl clinical trials

Explore recruiting ctcl clinical trials.

Recruiting ctcl studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Ctcl trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Single-arm, Phase II Study to Evaluate the Efficacy and Safety of Linperlisib (YY-20394) Monotherapy in Patients with Relapsed or Refractory Peripheral T/NK Cell or Cutaneous T Cell Lymphoma

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 1/2, Open-Label, Multicenter Study to Investigate the Safety, Pharmacokinetics, and Efficacy of Fadraciclib (CYC065), an Oral CDK2/9 Inhibitor, in Subjects with Advanced Solid Tumors and Lymphoma.

Spain

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Open-Label, Phase 2 Study to Assess the Safety of Mogamulizumab Given Every 4 Weeks Following Induction in Participants with Relapsed/Refractory Cutaneous T-Cell Lymphoma (CTCL)

Spain, France

Therapeutic exploratory (Phase II) EU CTIS Study details

BeCALM - Brentuximab vedotin in CutAneous T-cell Lymphomas (CTCL): post-allogeneic hematopoietic stem cell transplant Maintenance

France

Therapeutic confirmatory (Phase III) EU CTIS Study details

An Open-Label, Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of PTX-100 Monotherapy in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma.

Italy, France

Therapeutic exploratory (Phase II) EU CTIS Study details

CITY

Spain, France

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

Ctcl trials by city

Ctcl in Toronto Ctcl in Vancouver Ctcl in Montreal Ctcl in Calgary Ctcl in Edmonton Ctcl in Ottawa Ctcl in Winnipeg Ctcl in Quebec City Ctcl in Hamilton Ctcl in Kitchener Ctcl in London Ctcl in Halifax Ctcl in New York Ctcl in Los Angeles Ctcl in Chicago Ctcl in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease